"10.1371_journal.pone.0117242","plos one","2015-02-13T00:00:00Z","Peter J Holst; Benjamin A H Jensen; Emeline Ragonnaud; Allan R Thomsen; Jan P Christensen","Department of International Health, Immunology and Microbiology, University of Copenhagen, The Panum Institute, Copenhagen, Denmark; Centre for Medical Parasitology, Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark","Conceived and designed the experiments: PJH ART JPC. Performed the experiments: PJH BHJ ER. Analyzed the data: PJH BHJ ER. Contributed reagents/materials/analysis tools: PJH JPC. Wrote the paper: PJH ART JPC.","The authors PJH, JPC and ART are inventors on the patent family “a nucleotide vaccine”, originally published as WO2007062656, and the application “priming an immune response”, published as WO2010057501A1. This IPR is controlled by the University of Copenhagen and therefore JPC, ART, ER can declare no conflict of interest. PJH further have equity in the Biotech company InProTher ApS which relate to the use of the MHC class II associated Invariant Chain as a T cell adjuvant and this should therefore be disclosed for transparency reasons, although the LCM virus vaccines studied here have limited commercial potential and InProTher ApS does not have commercial rights within the arenavirus field. The authors PJH, ART, JPC and ER are all full time employees at the University of Copenhagen The above declarations does not alter the adherence for any of the authors to all PLOS ONE policies on sharing data and materials.","2015","02","Peter J Holst","PJH",5,TRUE,3,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
